Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

222 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future.
Saura-Esteller J, de Jong M, King LA, Ensing E, Winograd B, de Gruijl TD, Parren PWHI, van der Vliet HJ. Saura-Esteller J, et al. Among authors: parren pwhi. Front Immunol. 2022 Jun 16;13:915837. doi: 10.3389/fimmu.2022.915837. eCollection 2022. Front Immunol. 2022. PMID: 35784326 Free PMC article. Review.
A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell-Mediated Antitumor Responses in Human B-cell Malignancies.
de Weerdt I, Lameris R, Scheffer GL, Vree J, de Boer R, Stam AG, van de Ven R, Levin MD, Pals ST, Roovers RC, Parren PWHI, de Gruijl TD, Kater AP, van der Vliet HJ. de Weerdt I, et al. Among authors: parren pwhi. Cancer Immunol Res. 2021 Jan;9(1):50-61. doi: 10.1158/2326-6066.CIR-20-0138. Epub 2020 Nov 11. Cancer Immunol Res. 2021. PMID: 33177109
A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell-Mediated Immune Response against EGFR-Expressing Tumors.
King LA, Toffoli EC, Veth M, Iglesias-Guimarais V, Slot MC, Amsen D, van de Ven R, Derks S, Fransen MF, Tuynman JB, Riedl T, Roovers RC, Adang AEP, Ruben JM, Parren PWHI, de Gruijl TD, van der Vliet HJ. King LA, et al. Among authors: parren pwhi. Cancer Immunol Res. 2023 Sep 1;11(9):1237-1252. doi: 10.1158/2326-6066.CIR-23-0189. Cancer Immunol Res. 2023. PMID: 37368791
222 results